Walmart (NYSE:WMT) is set to become the first brick-and-mortar retailer to sell Lingo, Abbott Laboratories’ (NYSE:ABT) over-the-counter glucose monitoring system, which is available without a prescription, Axios reported on Tuesday. The big box store is expected to launch the Lingo ...

Core Insights - Walmart is set to become the first U.S. retailer to offer an over-the-counter continuous glucose monitor in physical stores, specifically Abbott Laboratories' Lingo, which will be available in over 3,500 locations and online [1] Company Summary - Walmart's initiative to sell Abbott's Lingo glucose monitor marks a significant step in expanding access to diabetes management tools for consumers [1] - The rollout of Lingo in Walmart stores highlights the growing trend of retailers diversifying their health product offerings [1] Industry Summary - The introduction of over-the-counter continuous glucose monitors in retail settings reflects a broader shift towards consumer empowerment in health management [1] - This move may influence other retailers to consider similar health product offerings, potentially reshaping the competitive landscape in the healthcare retail sector [1]

Core Insights - Abbott Laboratories (NYSE:ABT) is recognized as one of the top medical device stocks, with Benchmark initiating coverage on October 10, setting a price target of $145 and a Buy rating, highlighting the company's reliable performance in a dynamic global market [1] Group 1: Business Strategy and Market Position - Abbott's business strategy is characterized by its independence from any single treatment, product, or market, which contributes to its resilience [1] - The company is expected to see a resurgence in its Diagnostics business by 2026, driven by a new molecular nucleic acid testing platform for blood screening, despite current challenges from post-pandemic declines in COVID-19 testing and pressures in China [2] Group 2: Investment and Expansion - Benchmark noted Abbott's proactive approach to potential trade disruptions, citing a $500 million investment in new U.S. facilities and expansions planned for the upcoming year, positioning the company favorably for future tariff discussions [3] - Abbott Laboratories is a leading global healthcare company, producing a diverse range of products including branded generic medications, medical devices, diagnostics, and nutritional items [3]

Key Takeaways Abbott's Q3 adjusted earnings met estimates despite a revenue miss on strong year-over-year growth.Tariffs and weaker Diagnostics sales in China narrowed margins and curbed investor enthusiasm.Diversified growth in Medical Devices and Nutrition supports Abbott's resilience amid trade headwinds.Shares of Abbott (ABT) have edged up 0.7% since the company’s third-quarter 2025 earnings release on Oct. 15, 2025. The company reported a strong year-over-year increase in adjusted earnings and revenues ...

Market Overview - The stock market rebounded this week with the S&P 500 and Nasdaq increasing by 1.7% and 2.1% respectively after previous losses of over 2% [1] - Concerns about U.S.-China trade, the federal government shutdown, and regional bank credit quality influenced market fluctuations [1] Financial Sector Performance - Zion and Western Alliance disclosed bad loans, leading to a selloff in financial stocks, with Zion and Western Alliance shares dropping 13% and nearly 11% respectively [1] - Capital One, a credit card issuer, fell 5.5% on Thursday but rebounded 4% the following session, reflecting market volatility [1] - Wells Fargo reported a strong third quarter, beating both top and bottom-line estimates, and raised its ROTCE target from 15% to 17%-18% [1] - Goldman Sachs achieved record third-quarter revenue with a 42% increase in investment banking fees compared to last year, although shares fell 1.8% for the week [1] - BlackRock reported better-than-expected results, with shares rising 2.5% for the week, and announced a new money market fund compliant with the GENIUS Act [1] Company-Specific Developments - Abbott Laboratories had another disappointing quarter, leading to a price target reduction from $145 to $140 and a downgrade to a 3 rating [1] - DuPont announced a spinoff of its electronics business Qnity, with shares jumping 8% for the week, and is trading at a 38% discount to its estimated sum of parts [2] - Honeywell will spin off its Solstice Advanced Materials unit, with a 1% weekly advance in its stock [2] - Salesforce shares gained during Dreamforce week, with a forecast of $60 billion in annual revenue for fiscal year 2030, exceeding market expectations [2]

Core Insights - The article emphasizes the importance of conducting personal in-depth research and due diligence before making investment decisions, highlighting the inherent risks involved in trading [3]. Company and Industry Analysis - The analysis is intended for informational purposes only and should not be considered as professional investment advice, indicating a focus on providing insights rather than direct recommendations [3][4]. - There is a clear distinction made between the opinions expressed in the article and those of Seeking Alpha as a whole, suggesting that the views may not represent the platform's official stance [4].

Core Insights - Abbott's Q3 2025 financial report shows a global sales of $11.369 billion, a year-on-year increase of 6.9%, with organic growth of 5.5% excluding foreign exchange impacts [2] - The adjusted diluted earnings per share (EPS) is $1.30, reflecting a 7.4% increase year-on-year, and the operating margin improved to 23.0% [2] - The company maintains its full-year guidance, expecting organic growth of 7.5%–8.0% excluding COVID-19 testing impacts, with adjusted EPS narrowed to $5.12–$5.18, indicating double-digit growth [2][24] Business Breakdown Medical Devices - Medical device sales reached $5.448 billion, a 14.8% increase year-on-year, with organic growth of 12.5%, making it the core driver of overall performance [4] - Key growth areas include diabetes care, particularly the continuous glucose monitoring (CGM) products, which generated approximately $2.057 billion in sales [4][6] Diagnostics - Diagnostics sales totaled $2.253 billion, down 6.6% year-on-year, primarily due to a significant decline in COVID-19 testing revenue [8] - Excluding COVID-19 testing, the diagnostics business showed slight positive growth of 0.4%, indicating resilience in core operations [8] Nutrition - Nutrition sales amounted to $2.153 billion, with organic growth of 4.0%, driven by strong performance in adult nutrition products [10] - Adult nutrition products like Ensure and Glucerna are gaining traction among aging and diabetes management populations [10] Established Pharmaceuticals - International sales in established pharmaceuticals reached $1.511 billion, with a year-on-year growth of 7.5% and organic growth of 7.1%, particularly in emerging markets [13] - The strategy of high-quality prescription drugs combined with local manufacturing is enhancing brand recognition [13] Regional and Profit Performance - International market revenue was $7.070 billion, accounting for over 60% of total sales, with a growth of 9.9% [17] - The U.S. market grew by 2.3%, reflecting a recovery in routine business post-pandemic [17] - The adjusted operating margin improved to 23.0%, with R&D expenses increasing by 7.5%, indicating continued investment in core innovation projects [17] Future Outlook - Management believes that the sustained growth in the medical device sector, steady recovery in diagnostics, and stable performance in nutrition and generics will support achieving the expected full-year performance [18] - Key variables for medium to long-term performance include the expansion of structural heart indications and the penetration rate of CGM products [22]

Core Insights - NextEra Energy has received a 20-year license renewal for its Point Beach Nuclear Plant, allowing operations through 2050 and 2053, which supports its energy initiatives [1] - NextEra Energy is a leading electric utility holding company focused on scaling electricity and expanding resources to meet increasing U.S. energy demand [2] - The company reported a 10.4% year-over-year sales increase to $6.7 billion and a 25% rise in net income to $2.03 billion in its most recent quarter [6] Financial Performance - NextEra's stock is trading at $85.05 with a forward annual dividend of $2.27, yielding approximately 2.7% and a dividend payout ratio of 59.95% [6] - Lowe's Companies reported a 1.6% year-over-year sales increase to $23.96 billion and a net income rise of 0.6% to $2.4 billion, with stock trading at $243.10 and a forward annual dividend of $4.80, yielding just under 2% [10] - Atmos Energy reported a 19.6% sales increase to $838.8 million and a net income rise of 12.6% to $186.4 million, with stock trading at $176.37 and a forward annual dividend of $3.48, yielding approximately 2% [14] - Abbott Laboratories saw a 7.4% sales increase to $11.14 billion and a 36.6% rise in net income to $1.78 billion, with stock trading at $127.63 and a forward annual dividend of $2.36, yielding approximately 1.8% [19] - Linde Plc reported a 2.8% sales increase to $8.5 billion and a 6.2% rise in net income to $1.77 billion, with stock trading at $444.24 and a forward annual dividend of $6.00, yielding approximately 1.4% [23] Analyst Ratings - NextEra Energy has a consensus rating of "Moderate Buy" with a score of 4.05/5 from 21 analysts, reflecting increased sentiment over the last three months [7] - Lowe's Companies has a consensus rating of "Moderate Buy" with a score of 4.21/5 from 29 analysts, showing a slight decrease in sentiment [11] - Atmos Energy has a consensus rating of "Moderate Buy" with a score of 3.64/5 from 14 analysts, with consistent but slightly declining sentiment [15] - Abbott Laboratories has a consensus rating of "Strong Buy" with a score of 4.45/5 from 29 analysts, strengthening from a "Moderate Buy" three months ago [20] - Linde Plc has a consensus rating of "Strong Buy" with a score of 4.41/5 from 27 analysts, with no analysts holding a "sell" rating [24]

Core Viewpoint - Abbott Laboratories' recent price drop is seen as a buying opportunity, with analysts and institutional investors showing increasing interest in the stock [3][4]. Group 1: Stock Performance and Analyst Sentiment - Abbott Laboratories' stock price is currently at $127.31, with a 52-week range between $110.86 and $141.23, and a dividend yield of 1.85% [3]. - Analyst trends indicate a positive sentiment, with a consensus forecast predicting a 10% gain ahead of the earnings release, potentially reaching an all-time high [4]. - Institutional investors have been consistently purchasing Abbott's stock, with a buying ratio of approximately $1.50 for every $1.00 sold over the past year, increasing to $3.25 to $1 as of mid-October [4]. Group 2: Financial Performance - Abbott's Q3 revenue growth was slightly below analysts' expectations, missing the consensus forecast by 0.17%, but still reported a 6.9% revenue growth [8][10]. - The company achieved a 12.5% organic growth in Medical Devices and 7.1% in Established Pharmaceuticals, while Diagnostics saw a decline of 7.8% due to COVID-19-related sales [10]. - Adjusted operating margin increased by 40 basis points, with operating earnings rising by 10.6% and net income growing by 7.5%, resulting in an adjusted EPS of $1.30, up 7.45% year-over-year [11]. Group 3: Dividend and Growth Outlook - Abbott Laboratories has a reliable dividend yield of 1.85%, with an annual dividend of $2.36 and a track record of 54 years of dividend increases [12][13]. - The company maintains a low dividend payout ratio of 29.57%, indicating strong earnings growth potential, with projections of low-double-digit growth over the next five years [13]. - Abbott's diversified product portfolio across various segments helps mitigate risks from sector-specific slowdowns, positioning the company well for sustained growth and shareholder returns [14].

Core Insights - Goldman Sachs has added four new stocks to its Conviction List, which are expected to have double-digit upside potential and three of which offer reliable dividends [4][5][6]. Group 1: Goldman Sachs Conviction List - The Conviction List is a curated selection of stocks that Goldman Sachs analysts believe will outperform the market, focusing on themes like artificial intelligence and sustainability [2][4]. - The four new stocks added in October are Abbott Laboratories, Air Products and Chemicals, Hershey, and Madison Square Garden Entertainment [5][6]. Group 2: Stock Details - **Abbott Laboratories**: Offers a 1.74% dividend with a target price of $157, indicating a potential 17% gain [7][8]. - **Air Products and Chemicals**: Provides a 2.63% dividend and has a target price of $335, suggesting a 23% upside [9][15]. - **Hershey**: Features a 2.82% dividend with a target price of $222, representing a potential 19% gain [16][20]. - **Madison Square Garden Entertainment**: A live entertainment company with a target price of $52, indicating a 15% upside [21][23].